A T Podany1, J Leon-Cruz2, J Hakim3, K Supparatpinyo4, A Omoz-Oarhe5, D Langat6, N Mwelase7, C Kanyama8, A Gupta9, C A Benson10, R E Chaisson11, S Swindells1, C V Fletcher1. 1. University of Nebraska Medical Center, Omaha, NE, USA. 2. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 3. Parirenyatwa CRS, Harare, Zimbabwe. 4. Chiang Mai University HIV Treatment CRS, Chiang Mai, Thailand. 5. Molepolole Clinical Research Site, Molepolole, Botswana. 6. Kenya Medical Research Institute/Walter Reed Project Clinical Research Center CRS, Kericho, Kenya. 7. University of the Witwatersrand Helen Joseph CRS, Johannesburg, South Africa. 8. Malawi CRS, Lilongwe, Malawi. 9. Johns Hopkins Hospital, Baltimore, MD, USA. 10. University of California San Diego, San Diego, CA, USA. 11. Johns Hopkins University, Baltimore, MD, USA.
Abstract
BACKGROUND: The use of rifamycin antibiotics for TB prevention carries a risk of detrimental drug-drug interactions with concomitantly used ART. OBJECTIVES: To evaluate the interaction of the antiretroviral drug nevirapine in combination with 4 weeks of daily rifapentine and isoniazid for TB prevention in people living with HIV. METHODS: Participants were individuals enrolled in the BRIEF-TB study receiving nevirapine and randomized to the rifapentine/isoniazid arm of the study. Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination. Nevirapine apparent oral clearance (CL/F) was estimated and the geometric mean ratio (GMR) of CL/F prior to and during rifapentine/isoniazid was calculated. RESULTS: Seventy-eight participants had evaluable PK data: 61 (78%) female, 51 (65%) black non-Hispanic and median (range) age of 40 (13-66) years. Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL. Sixty out of 78 participants (77%) had nevirapine concentrations ≥3000 ng/mL at both week 2 and 4. Median (IQR) nevirapine CL/F values were: week 0 pre-rifapentine/isoniazid, 2.03 (1.58-2.58) L/h; and during rifapentine/isoniazid, 2.62 (1.81-3.42) L/h. The GMR (90% CI) for nevirapine CL/F was 1.30 (1.26-1.33). CONCLUSIONS: The CL/F of nevirapine significantly increased with concomitant rifapentine/isoniazid. The decrease in nevirapine trough concentrations during rifapentine/isoniazid therapy suggests induction of nevirapine metabolism, consistent with known rifapentine effects. The magnitude of this drug-drug interaction suggests daily rifapentine/isoniazid for TB prevention should not be co-administered with nevirapine-containing ART.
BACKGROUND: The use of rifamycin antibiotics for TB prevention carries a risk of detrimental drug-drug interactions with concomitantly used ART. OBJECTIVES: To evaluate the interaction of the antiretroviral drug nevirapine in combination with 4 weeks of daily rifapentine and isoniazid for TB prevention in people living with HIV. METHODS: Participants were individuals enrolled in the BRIEF-TB study receiving nevirapine and randomized to the rifapentine/isoniazid arm of the study. Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination. Nevirapine apparent oral clearance (CL/F) was estimated and the geometric mean ratio (GMR) of CL/F prior to and during rifapentine/isoniazid was calculated. RESULTS: Seventy-eight participants had evaluable PK data: 61 (78%) female, 51 (65%) black non-Hispanic and median (range) age of 40 (13-66) years. Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL. Sixty out of 78 participants (77%) had nevirapine concentrations ≥3000 ng/mL at both week 2 and 4. Median (IQR) nevirapine CL/F values were: week 0 pre-rifapentine/isoniazid, 2.03 (1.58-2.58) L/h; and during rifapentine/isoniazid, 2.62 (1.81-3.42) L/h. The GMR (90% CI) for nevirapine CL/F was 1.30 (1.26-1.33). CONCLUSIONS: The CL/F of nevirapine significantly increased with concomitant rifapentine/isoniazid. The decrease in nevirapine trough concentrations during rifapentine/isoniazid therapy suggests induction of nevirapine metabolism, consistent with known rifapentine effects. The magnitude of this drug-drug interaction suggests daily rifapentine/isoniazid for TB prevention should not be co-administered with nevirapine-containing ART.
Authors: K E Dooley; E E Bliven-Sizemore; M Weiner; Y Lu; E L Nuermberger; W C Hubbard; E J Fuchs; M T Melia; W J Burman; S E Dorman Journal: Clin Pharmacol Ther Date: 2012-05 Impact factor: 6.875
Authors: Anthony T Podany; Yajing Bao; Susan Swindells; Richard E Chaisson; Janet W Andersen; Thando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A Benson; Peter Kim; Courtney V Fletcher Journal: Clin Infect Dis Date: 2015-06-16 Impact factor: 9.079
Authors: Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson Journal: N Engl J Med Date: 2019-03-14 Impact factor: 91.245
Authors: Kelly E Dooley; Radojkam Savic; Akshay Gupte; Mark A Marzinke; Nan Zhang; Vinodh A Edward; Lisa Wolf; Modulakgotla Sebe; Morongwe Likoti; Mark J Fyvie; Innocent Shibambo; Trevor Beattie; Richard E Chaisson; Gavin J Churchyard Journal: Lancet HIV Date: 2020-03-30 Impact factor: 12.767
Authors: David W Haas; Anthony T Podany; Yajing Bao; Susan Swindells; Richard E Chaisson; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A Benson; Paxton Baker; Courtney V Fletcher Journal: Pharmacogenet Genomics Date: 2021-01 Impact factor: 2.000
Authors: Andrzej Bienczak; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; A Sarah Walker; Andrew Owen; Diana M Gibb; David Burger; Helen McIlleron; Paolo Denti Journal: J Antimicrob Chemother Date: 2016-10-05 Impact factor: 5.790
Authors: Shetty Ravi Dyavar; Timothy M Mykris; Lee C Winchester; Kimberly K Scarsi; Courtney V Fletcher; Anthony T Podany Journal: Sci Rep Date: 2020-07-28 Impact factor: 4.379
Authors: X J Zhou; L B Sheiner; R T D'Aquila; M D Hughes; M S Hirsch; M A Fischl; V A Johnson; M Myers; J P Sommadossi Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.191
Authors: Michelle M Pham; Anthony T Podany; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Wadzanai Samaneka; Ayotunde Omoz-Oarhe; Deborah Langat; Constance A Benson; Richard E Chaisson; Susan Swindells; Courtney V Fletcher Journal: Antimicrob Agents Chemother Date: 2022-08-09 Impact factor: 5.938